Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: We obtained 3 PR, 4 SD and 13 PD. Overall response rate was 15% (95% CI: 3% to 38%) (intent to treat analysis: 13%; 95% CI: 3% to 34%). The median durations of response and survival were 9 and 5 months, respectively. Grade 3-4 WHO toxicity included diarrhoea (17%), mucositis (22%), leukopenia (17%). CONCLUSIONS:
|
Authors | E Maiello, V Gebbia, F Giuliani, A Testa, F Giotta, N Gebbia, G Colucci |
Journal | La Clinica terapeutica
(Clin Ter)
1998 Sep-Oct
Vol. 149
Issue 5
Pg. 351-5
ISSN: 0009-9074 [Print] Italy |
PMID | 10052247
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antibiotics, Antineoplastic
- Antimetabolites, Antineoplastic
- Antineoplastic Agents, Phytogenic
- Epirubicin
- Etoposide
- Leucovorin
- Fluorouracil
|
Topics |
- Aged
- Antibiotics, Antineoplastic
(therapeutic use)
- Antimetabolites, Antineoplastic
(therapeutic use)
- Antineoplastic Agents, Phytogenic
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
- Drug Resistance, Neoplasm
- Epirubicin
(therapeutic use)
- Etoposide
(therapeutic use)
- Female
- Fluorouracil
(therapeutic use)
- Humans
- Leucovorin
(therapeutic use)
- Male
- Neoplasm Staging
- Pancreatic Neoplasms
(drug therapy, pathology)
|